Lexicon Pharmaceuticals Inc (LXRX) - Total Liabilities
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has total liabilities worth $65.96 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lexicon Pharmaceuticals Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See LXRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Lexicon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Standard Motor Products Inc
NYSE:SMP
|
USA | $1.34 Billion |
|
Ripley Corp
SN:RIPLEY
|
Chile | CL$3.02 Trillion |
|
Jiangsu High Hope International Group Corp
SHG:600981
|
China | CN¥23.74 Billion |
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
China | CN¥636.49 Million |
|
Changchun Faway Automobile Components Co Ltd
SHG:600742
|
China | CN¥12.67 Billion |
|
CCP Contact Probe Co Ltd
TWO:6217
|
Taiwan | NT$3.50 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥735.96 Million |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
Poland | zł9.98 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Lexicon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LXRX market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexicon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Lexicon Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $77.45 Million | -49.20% |
| 2024-12-31 | $152.47 Million | +11.85% |
| 2023-12-31 | $136.32 Million | +76.64% |
| 2022-12-31 | $77.17 Million | +231.02% |
| 2021-12-31 | $23.31 Million | -50.83% |
| 2020-12-31 | $47.42 Million | -84.23% |
| 2019-12-31 | $300.61 Million | -3.20% |
| 2018-12-31 | $310.54 Million | -19.22% |
| 2017-12-31 | $384.44 Million | +20.81% |
| 2016-12-31 | $318.22 Million | -13.76% |
| 2015-12-31 | $368.98 Million | +96.94% |
| 2014-12-31 | $187.36 Million | +80.16% |
| 2013-12-31 | $104.00 Million | -1.05% |
| 2012-12-31 | $105.10 Million | -20.94% |
| 2011-12-31 | $132.94 Million | +10.92% |
| 2010-12-31 | $119.86 Million | +27.15% |
| 2009-12-31 | $94.26 Million | +43.52% |
| 2008-12-31 | $65.68 Million | -20.60% |
| 2007-12-31 | $82.72 Million | -21.04% |
| 2006-12-31 | $104.77 Million | -21.18% |
| 2005-12-31 | $132.91 Million | +47.05% |
| 2004-12-31 | $90.39 Million | -23.39% |
| 2003-12-31 | $117.98 Million | +270.20% |
| 2002-12-31 | $31.87 Million | +47.42% |
| 2001-12-31 | $21.62 Million | +65.47% |
| 2000-12-31 | $13.06 Million | -7.34% |
| 1999-12-31 | $14.10 Million | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more